Magstim Horizon Inspire TMS system jpg
Magstim Horizon Inspire Transcranial Magnetic Stimulation Device Approved by UKCA for NHS & Private UK Clinics
December 05, 2024 04:02 ET | Magstim EGI
UKCA Approves Magstim Horizon Inspire TMS for NHS & Private UK Clinics. UK Made System for Patient Treatment of MDD, OCD and Decreasing Anxiety.
full_colour.png
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 14, 2024 07:00 ET | GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol delivery...
Magstim Inspire TMS system photo
FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic Stimulation System to treat Depression, OCD, Anxious Depression
November 12, 2024 08:11 ET | Magstim EGI
FDA clears Magstim INSPIRE Transcranial Magnetic Stimulation TMS system to treat patients with Depression, OCD, Anxious Depression
Two in Five American
Two in Five Americans Say Their Mood Worsens in Winter; 29% Say “Falling Back” Hurts Their Mental Health
October 30, 2024 10:00 ET | American Psychiatric Association
Washington, D.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- As the nation “falls back” to standard time, Americans are twice as likely to say their mood declines in the winter (41%) as they are to say it...
logo.png
Nexstim Receives NBS System 5 Order from European Customer
October 02, 2024 02:00 ET | Nexstim Oyj
Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS...
full_colour.png
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
September 03, 2024 07:05 ET | GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label...
full_colour.png
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
September 03, 2024 07:00 ET | GH Research PLC
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
Anxiety Disorders and Depression Treatment Global Market
Anxiety Disorders and Depression Treatment Global Market Report 2024-2032: Sturdy Medication Pipelines to Support Development, Economic Cost of Mental Illnesses to Drive Demand
August 30, 2024 04:15 ET | Research and Markets
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Anxiety Disorders and Depression Treatment Global Market Report, Forecast by Product, Indication, Country and Company Analysis 2024-2032" report has...
Solace-Psychology-logo.png
Solace Psychology Announce New Anxiety and Depression Counselling Services in Melbourne
August 28, 2024 09:00 ET | Solace Psychology
Carlton North, VIC, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Solace Psychology, regarded locally as the best psychologist melbourne, is happy to announce the launch of its anxiety and depression...
Association between temperature and depression
Digital Health App Data is used for Award-winning study that demonstrates correlation between temperature and depression
July 25, 2024 09:13 ET | juli
Boston, July 25, 2024 (GLOBE NEWSWIRE) -- Dr. Pip Clery from University College London (UCL) has been awarded the 2024 Royal College of Psychiatrists International Congress poster prize in the...